Looking at the stock market and its gyrations last week, do you still believe that the management of individual companies, any individual companies, has anything to do with short-term stock price movements?
I replied to your similar question on a different thread. In short, no i was never an employee of this company. I make such "bold statements" because I have owned and held shares since 1993,, including original spinoff-shares from Medchem, the parent company that was subsequently acquired by Bard. I have been observing the company for 23 years. Until a few years ago, it was a penny stock. The marketing arrangement with JNJ/Mitek brought Anika out of the penny-stock arena and into a listing on the S&P600. Without the marketing partnership with Mitek/JNJ, Anika would still be a penny stock. Everything else that Anika has done on its own has been, in one way or another, messed up. Look at the dermal filler story (at one point the product was called Elevess; then they changed the name; it's been a disaster). Look at the Hyalomatrix story (a great product, basically an HA mesh for wound-healing, FDA-approved and really promising; look at the June 01, 2011 press release to see who they chose as their distribution partner). Look at the ophthalmic surgery product, which was their FIRST product -- it was absolutely great so long as Bausch&Lomb was their distribution partner, but when that arrangement fell apart (B&L was taken private), look at what happened. Look at the "Italian" acquisition. These are facts, historical facts. And the same CEO has been in charge for most of that time, not since day one (the original CEO was David Swann), but for a couple of decades. Also, look at the turnover in other executive positions. The most recent turnover situation was the fastest ever, and absolutely eye-popping as far as I'm concerned. All of this is public information, in press releases. Go and learn.
I did answer the question; you just didn't like the answer. And I have NEVER been "employed by them" -- I have owned shares of the company's common stock since 1993 and have neither sold nor purchased since then. I have been OBSERVING, for over 23 years. What I have observed has been, more often than not, case after case of poor-judgement-calls on the part of executive leadership. I am not alone in having made those observations, but perhaps you are too new to this message board to remember the "old days." I will give you a few examples, then I will stop pandering to your ignorance. Example number one: the Italian (Fidia) acquisition. The current CFO exhibited far more brains than the CEO when she was assigned to "fix the problems" that seemed to be pouring out like ants from an anthill, and Anika finally shut down a large part of the mess that they had purchased. They continue to make poor judgment calls about how to market the products that came with that acquisition. Example number two: choices of marketing partners. They did extremely well with JNJ (Mitek), and as far as I'm concerned it's been a wonderful miracle. Without JNJ/Mitek as their marketing partner for Orthovisc and Monovisc, Anika would still be a penny stock. Alas, Anika has teamed up with far more bad partners than good ones over the years. The biggest case in point would be their choice for distribution of Hyalomatrix, an HA-based wound healing material of great promise. Inexplicably, they chose Misonix, a small company that makes and sells sonicating equipment, as their distribution partnert (see June 01, 2011 Press Release). Oh, and the marketing problems viz the dermal filler product -- read about that and weep.
OK, Enough. There are plenty of other equally egregious examples, but these should give you a flavor of it. And alas, my nostrils are twitching about Cingal -- another really great product that I fear they will botch up again.